Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
foretinib
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Foretinib is an orally available small molecule multikinase inhibitor developed for the treatment of cancer. It targets multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, angiogenesis, and metastasis. Its primary targets include MET (hepatocyte growth factor receptor), vascular endothelial growth factor receptor 2 (VEGFR2), RON, AXL, TIE2, ERK, AKT, platelet-derived growth factor receptor beta (PDGFRB), FMS-like tyrosine kinase 3 (FLT3), and RET kinases. By inhibiting these kinases, foretinib blocks proliferation signals in cancer cells and impairs angiogenesis. The drug was discovered by Exelixis and further developed by GlaxoSmithKline. Foretinib has been investigated in clinical trials for various cancers including breast cancer, renal cell carcinoma (especially papillary subtype), gastric cancer, liver cancer, non-small cell lung cancer, head and neck cancers; however as of late 2015 its development appears to have been discontinued[1][2][3][5][7].
- Other names
- foretinib
02
Targets
AXL (AXL receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)MET (Mesenchymal-epithelial transition factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)MST1R (Recepteur d'origine nantais)TEK (Tie2)VEGFR2 (Vascular endothelial growth factor receptor 2)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)RAC1 (Rac family small GTPase 1)
Beyond the preview
Go deeper on foretinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on foretinib.